Allarity Therapeutics Files 8-K
Ticker: ALLR · Form: 8-K · Filed: Apr 18, 2024 · CIK: 1860657
Sentiment: neutral
Topics: sec-filing, 8-k, regulation-fd
TL;DR
Allarity Therapeutics filed an 8-K on 4/17/24. Check for updates.
AI Summary
On April 17, 2024, Allarity Therapeutics, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided text snippet.
Why It Matters
This filing indicates that Allarity Therapeutics, Inc. is providing updates to the SEC, which could contain important information for investors regarding financial status or significant business developments.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational details that would indicate a high risk.
Key Players & Entities
- Allarity Therapeutics, Inc. (company) — Registrant
- 0001213900-24-033929 (filing_id) — Accession Number
- 20240418 (date) — Filing Date
- April 17, 2024 (date) — Earliest Event Reported Date
- 001-41160 (ticker_symbol) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
The filing is primarily for a Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported was on April 17, 2024.
What is the SEC file number for Allarity Therapeutics, Inc.?
The SEC file number is 001-41160.
Where is Allarity Therapeutics, Inc. headquartered?
Allarity Therapeutics, Inc. is headquartered at 24 School Street, 2nd Floor, Boston, MA 02108.
What is the standard industrial classification for Allarity Therapeutics, Inc.?
The standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 558 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-04-18 07:00:30
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ALLR The Nasdaq Stock Mar
Filing Documents
- ea0204121-8k_allarity.htm (8-K) — 32KB
- ea020412101ex99-1_allarity.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-24-033929.txt ( ) — 236KB
- allr-20240417.xsd (EX-101.SCH) — 3KB
- allr-20240417_lab.xml (EX-101.LAB) — 33KB
- allr-20240417_pre.xml (EX-101.PRE) — 22KB
- ea0204121-8k_allarity_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Allarity Therapeutics, Inc. By: /s/ Thomas H. Jensen Thomas H. Jensen Chief Executive Officer Dated: April 18, 2024 2